A 15-year-old girl presented with a 2-month history of nodules on the arm. The initial biopsy showed an unspecific granulomatous reaction that was reported as non-diagnostic. Four months later, more nodules appeared in other locations and the pre-existing nodules had increased in size. Fever between 37.5 and 381C also appeared. A new histological evaluation showed an acute inflammatory infiltration, consisting of lymphocytes and monocytes, compatible with septal and lobular panniculitis. A short course of steroids was started, resulting in partial resolution of nodules and disappearance of fever.
Two months later, the patient experienced a high fever (391C) and new nodules. Physical examination showed significant swelling in both arms where the nodules had first appeared (Figure 1) , with indurated erythematous plaques and extensive skin ulceration. About 20 painless subcutaneous nodules of approximately 1 cm diameter were distributed around the neck, chest, abdomen and two on the left wrist; mild splenomegaly was also present.
Blood count showed: haemoglobin 10.1 g/dl, white cell count 3.3 Â 10 9 /l and platelet count 202 Â 10 9 /l. C-reactive protein was 5.7 mg/dl, beta 2 microglobulin 4 mg/l and erythrocyte sedimentation rate was 72 mm/h, lactate dehydrogenase (LDH) 936 mg/dl, transaminases: glutamic oxaloacetic transaminase 48 mg/dl and glutamic pyruvic transaminase 27 mg/dl. Serology for hepatitis A, B and C, herpes, cytomegalovirus and Epstein-Barr virus (EBV) as well as Brucella, were all negative. Rheumatological tests were also negative.
A third biopsy was performed, which showed a mononuclear cell infiltrate with moderate cell atypia, surrounding the fat cells. The cells reacted with CD3, CD8, CD45RO, CD56, Gramzyme, but not with CD20. Epstein-Barr was also negative. Clonal rearrangement of the T-cell receptor (TCR) was demonstrated by molecular biology.
Computed tomography scanning showed moderate hepatosplenomegaly and bilateral axillary lymph nodes larger than 1 cm, whereas a Gallium scan was positive in both arms. Bone marrow trephine and flow cytometry bone marrow studies were normal. No evidence of hemophagocytic syndrome was found. The patient was diagnosed with panniculitic T-cell lymphoma; stage VI B, with an International Prognostic Index (IPI) of 2.
She was treated with the MEGACHOD scheme (cyclophosphamide: 1500 mg/m although the fever resolved, disease progression with an increase in the indurated areas was observed 2 weeks after the first MEGACHOD, and FMD (fludarabine 25 mg/m 2 days 1, 2 and 3, mitoxantrone 10 mg/m 2 day 1 and dexamethasone 20 mg days 1-5) was immediately administered. Although an initial response was observed with reduction in the arm infiltration, as the peripheral counts had not recovered by 6 weeks, the second course of chemotherapy was delayed. Unfortunately, by week þ 6 progression in both arms was again observed.
Salvage therapy was initiated with CAMPATH IH 30 mg/day for 10 days, from days À24 to À10, followed by a allogeneic stem cell transplant, a human leukocyte antigen identical-related sibling donor was available. Stable disease was observed after CAMPATH and she underwent the allogeneic transplant using fractionated total body irradiation (TBI) 12 Gy days À7 to À5 (6 Gy per day), and VP-16, 60 m/kg day À3; stem cells were collected from peripheral blood, mobilized with granulocyte colonystimulating factor (6.7 Â 10 6 CD34/kg). Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine 0.5 mg/kg/12 h from days À9 to À2, and 1.5 mg/kg/12 h from À2, adjusted to blood levels.
No complications were observed during the transplant, and by day þ 21, the patient reached full donor chimerism in the marrow CD3 and CD15 lineages.
No acute or chronic GVHD occurred, and scarred cutaneous lesions remain where the first lesions had initially appeared. Gallium and positron emission tomography scans performed 6 months after transplant were completely normal, and 31 months after allogeneic transplantation, the patient remains asymptomatic and in complete remission (CR).
Subcutaneous T-cell panniculitic lymphoma (SPTCL) is an uncommon cutaneous T-cell lymphoma. It was first described in 1991. 1 Characteristically, delay and difficulty in making a diagnosis are common features of SPTCL. [2] [3] [4] [5] Misdiagnosis is not uncommon owing to the indolent course of the disease, which can mimic an unspecific panniculitis. 6 In our report three biopsies and 6 months were required before the final diagnosis could be made, by which time the lymphoma had become aggressive.
Histology and immunochemistry showed a characteristic pattern of infiltration by atypical lymphocytes surrounding the fat spaces, in a panniculitic-like pattern (Figure 2) , with positive cytotoxic T-cell markers.
The final diagnosis was confirmed by the characteristic histology and immunohistochemistry together with TCR clonality. 6, 7 Reports in the literature describe remission with schedules such as CHOP and FMD. 2, 3 However, our patient progressed in the third week after MEGACHOD and, although an initial response to FMD was observed, early progression occurred.
Owing to the presence of refractory disease with high LDH and the availability of a sibling donor we decided to perform an allogeneic transplant. 3, 8, 9 In an effort to overcome disease refractoriness, we used antiCD52 (Campath 1H) 10 immediately before the transplant (days À24 to À10) and TBI as conditioning, substituting VP16 for the cyclophosphamide because of the lack of sensitivity to cyclophosphamide observed with the MegaCHOD scheme. The patient achieved clinical remission and she is in CR 31 months post transplant.
In summary, we have described a successful outcome using CAMPATH I and allogeneic peripheral stem cell transplantation in a girl with a primary refractory subcutaneous T-cell panniculitic lymphoma. Owing to the bad prognosis of this disease, this could be a reasonable approach for young patients with refractory/relapse disease after conventional chemotherapy. Letter to the Editor
